/ Media

News Features

Access media kits and related information for our featured news stories.

20 Nov 2014

Flu Season Resources

On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).


Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.


Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.


On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.


Genentech will present important new ophthalmic data at the 49th Annual Meeting of the American Society of Retina Specialists (ASRS) from August 9-13 in San Diego.


Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.


gRide, Genentech's employee commuting program, has saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus.


Genentech Gives Back Week (June 11 - 16, 2012) is a unique opportunity for Genentech employees to support the communities where we live and work.


Genentech will present important new data on several cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).


Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.


On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.


October 18, 2010 is the 25th anniversary of Genentech's first product approval and the first recombinant biotech drug to be manufactured and marketed by a biotechnology company.


Genentech Fellow Napoleone Ferrara is the winner of the 2010 Lasker Award for clinical research, presented annually to an investigator "whose contributions have improved the clinical treatment of patients."


Genentech Goes to Town takes place September 13 to September 24 in South San Francisco, Vacaville, Oceanside and Hillsboro. The Genentech Goes to Town program supports our communities by providing employees with special "GenenMoney" to spend at local businesses.


Genentech Gives Back Week voluntary activities each day that help Genentech employees collectively make a difference in our communities. All employees are invited to participate in Genentech Gives Back as their time and interest allows.


On April 6, Genentech recognized the opening of its operations in Hillsboro, Oregon, home to a state-of-the-art biologic fill/finish facility and warehousing and distribution center.